share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  08/08 08:34
Moomoo AI 已提取核心訊息
On August 7, 2024, Conduit Pharmaceuticals Inc. entered into a License Agreement with AstraZeneca AB, granting Conduit exclusive rights to develop and commercialize certain intellectual property for HK-4 Glucokinase activators and a myeloperoxidase inhibitor for idiopathic male infertility. The agreement includes an upfront payment of $1.5 million, common stock issuance, and tiered sublicense revenue sharing. Conduit will initiate Phase II clinical trials for the licensed compounds, which have already shown favorable preclinical and Phase I data. Additionally, Conduit amended a previous funding agreement with St George Street Capital, allowing for other third-party project funders. The License and Issuance Agreements will be filed with the SEC as part of Conduit's Quarterly Report for Q3 2024.
On August 7, 2024, Conduit Pharmaceuticals Inc. entered into a License Agreement with AstraZeneca AB, granting Conduit exclusive rights to develop and commercialize certain intellectual property for HK-4 Glucokinase activators and a myeloperoxidase inhibitor for idiopathic male infertility. The agreement includes an upfront payment of $1.5 million, common stock issuance, and tiered sublicense revenue sharing. Conduit will initiate Phase II clinical trials for the licensed compounds, which have already shown favorable preclinical and Phase I data. Additionally, Conduit amended a previous funding agreement with St George Street Capital, allowing for other third-party project funders. The License and Issuance Agreements will be filed with the SEC as part of Conduit's Quarterly Report for Q3 2024.
2024年8月7日,Conduit Pharmaceuticals Inc.與阿斯利康Ab簽署了一份許可協議,授予Conduit獨家開發和商業化Hk-4葡萄糖激酶激動劑和用於特發性男性不育症的髓過氧化物酶抑制劑的某些知識產權的專有權利。該協議包括提前支付150萬美元、普通股發行和分層轉讓收益共享。Conduit將啓動已經展示了有利的臨床前和I期數據的許可化合物的II期臨床試驗。此外,Conduit修改了之前與St George Street Capital的資金協議,允許其他第三方項目出資者。許可和發行協議將作爲Conduit的2024年第三季度報告的一部分提交給美國證券交易委員會。
2024年8月7日,Conduit Pharmaceuticals Inc.與阿斯利康Ab簽署了一份許可協議,授予Conduit獨家開發和商業化Hk-4葡萄糖激酶激動劑和用於特發性男性不育症的髓過氧化物酶抑制劑的某些知識產權的專有權利。該協議包括提前支付150萬美元、普通股發行和分層轉讓收益共享。Conduit將啓動已經展示了有利的臨床前和I期數據的許可化合物的II期臨床試驗。此外,Conduit修改了之前與St George Street Capital的資金協議,允許其他第三方項目出資者。許可和發行協議將作爲Conduit的2024年第三季度報告的一部分提交給美國證券交易委員會。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息